| http://www.w3.org/ns/prov#value | - Enthusiasm for cardiovascular trials of MMP inhibitors waned after cancer trials showed side effects such as tendonitis (possibly related to inhibition of ADAMs) combined with a lack of efficacy and in one trial the possibility of harm [120].
|
